$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000110450617000005 Filed on November 02, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$31.40M	$17.41M	$13.72M
YoY Change	157.8%	26.9%	24.5%
% of Gross Profit
Research & Development	$33.95M	$26.68M	$23.43M
YoY Change	-38.13%	13.84%	21.92%
% of Gross Profit
Depreciation & Amortization	$730.0K	$720.0K	$680.0K
YoY Change	7.35%	5.88%	47.83%
% of Gross Profit
Operating Expenses	$65.35M	$44.08M	$37.15M
YoY Change	-2.54%	18.67%	22.81%
Operating Profit	-$65.35M	-$44.08M	-$37.15M
YoY Change	-2.53%	18.67%
Interest Expense	-$490.0K	$1.496M	$769.0K
YoY Change	-63.7%	94.54%	-218.31%
% of Operating Profit
Other Income/Expense, Net	$90.00K	$101.0K	$45.00K
YoY Change	200.0%	124.44%	-164.29%
Pretax Income	-$65.75M	-$45.15M	-$37.74M
YoY Change	-3.85%	19.66%	21.88%
Income Tax	-$370.0K	$27.00K	$25.00K
% Of Pretax Income
Net Earnings	-$65.38M	-$45.18M	-$37.76M
YoY Change	-4.41%	19.65%	21.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$852.3K	-$691.8K	-$610.2K
COMMON SHARES
Basic Shares Outstanding	76.59M shares	65.31M shares	61.88M shares
Diluted Shares Outstanding		65.31M shares	61.88M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$381.2M	$430.7M	$200.5M
YoY Change	134.44%	114.81%	-35.53%
Cash & Equivalents	$381.2M	$430.7M	$200.5M
Short-Term Investments
Other Short-Term Assets	$8.300M	$6.800M	$5.800M
YoY Change	43.1%	17.24%	-30.12%
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00
Other Receivables
Total Short-Term Assets	$389.4M	$437.5M	$206.3M
YoY Change	131.25%	112.06%	-35.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.40M	$8.975M	$10.30M
YoY Change	23.75%	-12.86%	27.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.000M	$1.600M	$1.900M
YoY Change	53.85%	-15.79%	850.0%
Total Long-Term Assets	$72.60M	$68.73M	$70.30M
YoY Change	4.39%	-2.24%	5.87%
TOTAL ASSETS
Total Short-Term Assets	$389.4M	$437.5M	$206.3M
Total Long-Term Assets	$72.60M	$68.73M	$70.30M
Total Assets	$462.0M	$506.2M	$276.6M
YoY Change	94.17%	83.01%	-28.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.67M	$9.348M	$8.300M
YoY Change	40.54%	12.63%	-23.85%
Accrued Expenses	$17.14M	$18.80M	$14.50M
YoY Change	1.9%	29.67%	46.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$44.66M	$28.77M	$23.50M
YoY Change	59.55%	22.41%	-49.68%
LONG-TERM LIABILITIES
Long-Term Debt	$55.57M	$55.39M	$34.70M
YoY Change	1.42%	59.62%
Other Long-Term Liabilities	$765.0K	$747.0K	$700.0K
YoY Change	10.39%	6.71%
Total Long-Term Liabilities	$56.33M	$56.14M	$35.40M
YoY Change	1.53%	58.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.66M	$28.77M	$23.50M
Total Long-Term Liabilities	$56.33M	$56.14M	$35.40M
Total Liabilities	$101.0M	$84.90M	$58.80M
YoY Change	20.98%	44.39%	25.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$957.9M	-$892.5M
YoY Change	25.18%
Common Stock	$766.0K	$766.0K
YoY Change	23.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$361.1M	$421.3M	$217.8M
YoY Change
Total Liabilities & Shareholders Equity	$462.0M	$506.2M	$276.6M
YoY Change	94.17%	83.01%	-28.29%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$65.38M	-$45.18M	-$37.76M
YoY Change	-4.41%	19.65%	21.96%
Depreciation, Depletion And Amortization	$730.0K	$720.0K	$680.0K
YoY Change	7.35%	5.88%	47.83%
Cash From Operating Activities	-$48.22M	-$38.24M	-$30.98M
YoY Change	-16.8%	23.43%	28.92%
INVESTING ACTIVITIES
Capital Expenditures	-$1.700M	-$450.0K	-$1.300M
YoY Change	120.78%	-65.38%	51.16%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.700M	-$450.0K	-$1.300M
YoY Change	120.78%	-65.38%	51.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$377.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	430.0K	378.2M	9.690M
YoY Change	-97.94%	3803.3%	1081.71%
NET CHANGE
Cash From Operating Activities	-48.22M	-38.24M	-30.98M
Cash From Investing Activities	-1.700M	-450.0K	-1.300M
Cash From Financing Activities	430.0K	378.2M	9.690M
Net Change In Cash	-49.49M	339.5M	-22.59M
YoY Change	30.65%	-1603.05%	-6.15%
FREE CASH FLOW
Cash From Operating Activities	-$48.22M	-$38.24M	-$30.98M
Capital Expenditures	-$1.700M	-$450.0K	-$1.300M
Free Cash Flow	-$46.52M	-$37.79M	-$29.68M
YoY Change	-18.66%	27.32%	28.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76591009	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
CY2017Q3	insm	Accretion Of Backend Fee AccretionOfBackendFee	677000	USD
CY2016Q4	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	7071000	USD
CY2017Q3	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	8560000	USD
CY2016Q4	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	591000	USD
CY2017Q3	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	742000	USD
CY2016Q4	insm	Availableforsale Securities Gross Unrealized Gain Loss Numberof Securities AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities	0	security
CY2017Q3	insm	Availableforsale Securities Gross Unrealized Gain Loss Numberof Securities AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities	0	security
CY2017Q3	insm	Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption	1842150	shares
CY2016Q3	insm	Fair Value Level1 Level2 Level3 Transfers Amount FairValueLevel1Level2Level3TransfersAmount	0	USD
	insm	Fair Value Level1 Level2 Level3 Transfers Amount FairValueLevel1Level2Level3TransfersAmount	0	USD
CY2017Q3	insm	Fair Value Level1 Level2 Level3 Transfers Amount FairValueLevel1Level2Level3TransfersAmount	0	USD
	insm	Fair Value Level1 Level2 Level3 Transfers Amount FairValueLevel1Level2Level3TransfersAmount	0	USD
	insm	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	3109000	USD
	insm	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	1745000	USD
	insm	Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross	236370	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10439000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9348000	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
	us-gaap	Accretion Expense AccretionExpense	506000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16822000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18802000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1604000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2057000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-65000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	34000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	919164000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1313006000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	250000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	91000	USD
CY2016Q4	us-gaap	Assets Assets	237956000	USD
CY2017Q3	us-gaap	Assets Assets	506206000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	168407000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	437480000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	282876000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200518000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	162591000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	430678000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	162600000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	430700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-82358000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	268087000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62019889	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76568368	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62019889	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76568368	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	620000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	766000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37777000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107876000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45103000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-127166000	USD
CY2017Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	289000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Depreciation Depreciation	1756000	USD
	us-gaap	Depreciation Depreciation	2168000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.74
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6634000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13716000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.01
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38498000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	128000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6937000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17408000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47767000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37735000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107800000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45152000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-127171000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	49000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	62000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	361000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-921000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	230000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1052000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	769000	USD
	us-gaap	Interest Expense InterestExpense	2015000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	1496000	USD
	us-gaap	Interest Expense InterestExpense	4459000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2471000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3876000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	438000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	424000	USD
CY2016Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	138000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	472000	USD
CY2017Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	326000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	649000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	83473000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	84901000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237956000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	506206000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27989000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	28766000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	55000000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	41601000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	13399000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	54791000	USD
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	55388000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9820000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	380656000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-37760000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-107871000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1301000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3428000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88746000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111396000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-45179000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-127265000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-127300000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37760000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107871000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45179000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-127265000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	37149000	USD
	us-gaap	Operating Expenses OperatingExpenses	106349000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	44083000	USD
	us-gaap	Operating Expenses OperatingExpenses	123567000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-37149000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-106349000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-44083000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-123567000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4293000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	498000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	477000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1421000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1520000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	377000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	181000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	385000	USD
CY2016Q4	us-gaap	Other Assets OtherAssets	1329000	USD
CY2017Q3	us-gaap	Other Assets OtherAssets	1551000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-17000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	76000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	99000	USD
CY2016Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2017Q3	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	728000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	616000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	693000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	747000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	92000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	206000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	308000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3428000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1301000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	24800000	USD
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Secured Debt SecuredDebt	55000000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5816000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6802000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	377700000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	377700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	377703000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	128000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2953000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10020000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8975000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23433000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67851000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26675000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75800000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-765236000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-892501000	USD
CY2016Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2017Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13879000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13332000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4929910	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3904073	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	386668	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2207390	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	148771000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7116706	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8601293	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.30
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.92
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	143327000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8269230	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.88
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.42
CY2017Q3	us-gaap	Share Price SharePrice	28.50
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	73193000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	14123150	shares
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	14100000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	336135	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	154483000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	421305000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61878000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61871000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65312000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63199000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61878000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61871000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65312000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63199000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61878000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61871000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65312000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63199000	shares

Files In Submission

Name	View Source	Status
0001104506-17-000005-index-headers.html	Edgar Link	pending
0001104506-17-000005-index.html	Edgar Link	pending
0001104506-17-000005.txt	Edgar Link	pending
0001104506-17-000005-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insm-20170930.xml	Edgar Link	completed
insm-20170930.xsd	Edgar Link	pending
insm-20170930x10q.htm	Edgar Link	pending
insm-20170930xex101.htm	Edgar Link	pending
insm-20170930xex102.htm	Edgar Link	pending
insm-20170930xex311.htm	Edgar Link	pending
insm-20170930xex312.htm	Edgar Link	pending
insm-20170930xex321.htm	Edgar Link	pending
insm-20170930xex322.htm	Edgar Link	pending
insm-20170930_cal.xml	Edgar Link	unprocessable
insm-20170930_def.xml	Edgar Link	unprocessable
insm-20170930_lab.xml	Edgar Link	unprocessable
insm-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2017 Q4 Form 10-Q Financial Statement

#000110450617000005 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2017 Q4 Form 10-Q Financial Statement

#000110450617000005 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm